EUVIMEDEUVIMED entdecken
Crossref

Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma

Chenbo Yang, Jingbo Xiao, Na Zhao, Xiaonan Liu, Yiwei Li, Yinan Huang, Chongli Zhang, Kuisheng Chen, Miaomiao Sun

British Journal of Haematology · 2026-07 · 209 (1) · 136-148

DOI: 10.1111/bjh.70541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 11.05.2026. Verfasst von Chenbo Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin kappa-Chains, Clonal Evolution. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Young and Middle-aged Health Science and Technology Innovation Leading Talent Training Project of Henan Provice, Key Scientific Research Projects Plan of Henan Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy whose progression and relapse are influenced by clonal heterogeneity. Although serum free light chains (sFLCs) are key biomarkers for tumour burden assessment, the clinical value of λ, κ and their ratio remains controversial. This study investigated the associations of sFLC κ , λ and the κ /λ ratio with clinical features, cytogenetic abnormalities, prognosis and response to the VRd regimen (bortezomib, lenalidomide, dexamethasone) in newly diagnosed MM (NDMM) patients, aiming to optimize risk stratification. A retrospective analysis of 113 NDMM patients was conducted. Baseline clinical data, cytogenetic markers ( RB1 /D13S319/IGH/1q21/ P53 /1p32) and treatment responses were collected, with stratification by renal function. Tumour proliferation, apoptosis and angiogenesis were assessed by immunohistochemistry. Prognostic factors were evaluated using Kaplan–Meier and Cox regression analyses. A modified revised International Staging System (R‐ISS) (MR‐ISS) model incorporating sFLC κ was then developed and temporally externally validated. Abnormal sFLC κ indicated poor prognosis. Among NDMM patients with normal renal function, abnormal sFLC κ was significantly associated with adverse clinical features, high tumour burden, an anti‐apoptotic and angiogenic tumour microenvironment, D13S319 deletion and a lower rate of deep remission after VRd induction. Moreover, the MR‐ISS model demonstrated superior risk discrimination compared with the R‐ISS. In conclusion, abnormal sFLC κ is a potential marker of poor prognosis and suboptimal response to VRd therapy in NDMM. Integrating sFLC κ with the R‐ISS improves risk stratification, providing new evidence for clinical application of this biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunoglobulin kappa-ChainsClonal EvolutionHumansFemaleMaleAgedMiddle AgedDexamethasoneRetrospective StudiesPrognosisLenalidomideBiomarkers, TumorBortezomibAntineoplastic Combined Chemotherapy ProtocolsAdultRisk AssessmentAged, 80 and overPrecision Medicine

Stichwörter der Autor:innen

VRd regimenmultiple myelomarisk stratificationserum free kappa light chain

Substanzen

Immunoglobulin kappa-ChainsDexamethasoneLenalidomideBiomarkers, TumorBortezomib

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
  • Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Young and Middle-aged Health Science and Technology Innovation Leading Talent Training Project of Henan Provice
  • Key Scientific Research Projects Plan of Henan Higher Education Institutions

Zitieren

APA

Yang, C., Xiao, J., Zhao, N., Liu, X., Li, Y., Huang, Y., Zhang, C., Chen, K., & Sun, M. (2026). Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma. British Journal of Haematology, 209(1), 136-148. https://doi.org/10.1111/bjh.70541

Vancouver

Yang C, Xiao J, Zhao N, Liu X, Li Y, Huang Y, et al. Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma. British Journal of Haematology. 2026;209(1):136-148. doi:10.1111/bjh.70541

BibTeX
@article{Yang2026,
  author = {Yang, Chenbo and Xiao, Jingbo and Zhao, Na and Liu, Xiaonan and Li, Yiwei and Huang, Yinan and Zhang, Chongli and Chen, Kuisheng and Sun, Miaomiao},
  title = {Preliminary investigation into the association of serum free kappa light chains with risk stratification, clonal evolution and precision therapy in multiple myeloma},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {1},
  pages = {136--148},
  doi = {10.1111/bjh.70541}
}
Kostenlos starten →